Covestro concludes fiscal year 2025 within narrowed guidance range

Group sales at EUR 12.9 billion (–8.7%)EBITDA of EUR 740 million (–30.9%)Free Operating Cash Flow of EUR –283 millionSTRONG program with EUR 275 million in realized savingsPartnership with XRG completed; capital increase strengthens balance sheetOutl…

Covestro AG – Chief Executive Officer Dr Markus Steilemann will not extend his contract beyond May 31, 2028

Covestro, Fertiglobe, and TA’ZIZ sign Memorandum of Understanding to explore strategic ammonia collaboration

Exploring ammonia supply opportunities from Fertiglobe to key Covestro sites globallyAccess to low-carbon and green ammonia, supports transition towards more sustainable production pathwaysJoint assessment of enabling ammonia infrastructureExploratio…

Covestro AG decides to apply for switch from the Prime Standard to the General Standard of the Frankfurt Stock Exchange

XRG P.J.S.C. initiates process for the transfer of the shares held by the minority shareholders of Covestro AG to XRG P.J.S.C. (squeeze-out under German stock corporation law)

Dr. Rainer Seele Assumes Chairmanship of Covestro Supervisory Board – Dr. Richard Pott Steps Down After Many Years of Successful Service

Leadership transition in Supervisory Board following successful completion of strategic partnership with XRGDr. Rainer Seele has succeeded Dr. Richard Pott effective 20 December 2025  

Chief Financial Officer Christian Baier to leave Covestro upon expiry of his contract at his own request

Covestro and XRG commence strategic partnership: Transaction successfully closed

EUR 1.17 billion capital increase has been executed Closing marks official start of partnership

Covestro and XRG receive final outstanding regulatory approval for strategic partnership

German Foreign Investment Control approval receivedAll closing conditions fulfilled: transaction expected to close in the coming daysPartnership marks a new chapter of close cooperation with focus on disciplined,long-term value-creationCovestro about…

Results in line with expectations – cost-cutting measures proving effective

Group revenue falls to EUR 3.2 billion (–12%)  EBITDA at EUR 242 million at the upper end of the forecast  Consolidated net income at EUR –47 million  Free operating cash flow at EUR 111 million  EBITDA forecast for 2025 narrowed  Sustainable growth…

Covestro expands specialty isocyanate footprint with two former Vencorex sites in the US and Thailand

Strengthening of Solutions & Specialties segment  Step in long-term growth strategy  Further improving aliphatics production portfolio by acquiring sites for production of isocyanate derivatives in Freeport, USA and Rayong, Thailand 

Volatile market environment weighs on second quarter

Group sales of EUR 3.4 billion (–8.4%) due to price decline  EBITDA at EUR 270 million (–15.6%) in line with forecast  Consolidated net income at EUR –59 million  Free operating cash flow at EUR –228 million  Full-year forecast adjusted: EBITDA betw…